Detalhe da pesquisa
1.
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Mol Ther
; 29(4): 1529-1540, 2021 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388419
2.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Cancer Immunol Res
; 11(9): 1222-1236, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37378662
3.
Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
Blood
; 116(16): 2984-93, 2010 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-20606160
4.
B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.
Blood Cancer J
; 12(7): 99, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35778390
5.
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.
Br J Haematol
; 147(4): 471-83, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19751240
6.
Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.
Oncotarget
; 9(98): 37173-37184, 2018 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30647852
7.
Upregulation of AXL and ß-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance.
Blood Cancer J
; 11(2): 37, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602892